It's kinda weird to me that despite the company saying repeatedly that they met their primary endpoints, and that the results are clinically meaningful, and that they are confident they have pathways to partnership deals, that posters here are questioning the results and in effect saying the company is misrepresenting the effectiveness of the drug. It's not really a matter of opinion: the company has a legal obligation to report the results accurately, and in this case they say the trial met its endpoints.
Ann: Paradigms Supplementary Phase 2B Data, page-5
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.080(16.2%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 58.0¢ | 50.0¢ | $753.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3168 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 102000 | 2 |
View Market Depth
| Last trade - 12.31pm 04/12/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
